Vitamin D Levels in Epilepsy Patients at the Neurology Polyclinic, Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
DOI:
https://doi.org/10.37275/bsm.v7i12.949Keywords:
25 OHD, AEDs, Epilepsy, Vitamin DAbstract
Background: In epilepsy patients, treatment is often lifelong and anti-epileptic drugs (AEDs) can be divided into two general groups, namely drugs that affect cytochrome P-450 (CYP-450) such as carbamazepine, phenytoin, primidone, or valproic acid, and those that affect minimal cytochrome P-450 such as gabapentin, vigabatrin, levetiracetam, oxcarbazepine, or topiramate. AEDs include various drugs that can cause a decrease in vitamin D levels. Therefore, this study was aimed at examining vitamin D levels in epilepsy patients who took AEDs at the neurology polyclinic at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia.
Methods: This research is a descriptive study with a cross-sectional design using primary data obtained from the results of patient examinations using laboratory tests and secondary data from medical records.
Results: As many as 78% (14 subjects) who received monotherapy had vitamin D levels below normal, and 16 subjects, or 76%, who received polytherapy had vitamin D levels below normal (p = 0.907). A total of 13 (72%) subjects who received phenytoin had vitamin D levels below normal, as well as 5 (63%) subjects who received carbamazepine and 12 (92%) subjects who received other therapies (p = 0.235). A total of 12 (67%) subjects who received therapy for 1-3 years and 18 (86%) subjects who received therapy > 3 years had vitamin D levels below normal (p = 0,406).
Conclusion: Vitamin D deficiency is a crucial problem in epilepsy patients receiving AED therapy, where more than 75% of patients have vitamin D deficiency. In this study, vitamin D deficiency did not have a significant relationship with the type of therapy (monotherapy or polytherapy) or the type of drug used. used, duration of therapy, and frequency of sun exposure.
Authors
- Sri Handayani1
- Radiyati Umi Partan2*
- Zen Hafy2
- Fitri Octaviana3
- Citra Ananta Avis4
- Rini Nindela5
- Selly Marisdina5
- 1Student, Biomedical Doctoral Study Program, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
- 2Teaching Staff, Biomedical Doctoral Study Program, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
- 3Teaching Staff, Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
- 4Student, Neurology Specialist Study Program, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
- 5Teaching Staff, Department of Neurology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
Corresponding author Radiyati Umi Partan — radiandinadr@yahoo.co.id
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
